IDYA Stock: Price, Earnings History and SEC Filings
IDEAYA Biosciences, Inc. (IDYA) last traded at $31.96, down 2.83% on the latest session and down 16.8% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-1.22 against an analyst estimate of $-1.18, a miss of 3.4%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
IDYA earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 4, 2026 | $-1.22 | $-1.18 | -3.39% |
| Mar 2026 | May 5, 2026 | $-1.11 | $-1.07 | -3.74% |
| Dec 2025 | Feb 17, 2026 | $-0.94 | $-1.03 | +8.74% |
IDYA beat the analyst EPS estimate in 1 of its last 3 reported quarters. Source: Nasdaq.
How IDYA reacts to earnings
Across its last 8 earnings releases, IDYA moved 4.2% on average the next session, in either direction. It rose after 3 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-04 | Before open | +2.01% |
| 2026-05-05 | Before open | -0.35% |
| 2026-02-17 | Before open | +1.62% |
| 2025-11-04 | Before open | -2.81% |
| 2025-08-05 | Before open | -3.52% |
| 2025-05-06 | Before open | -13.29% |
| 2025-02-13 | Before open | -5.42% |
| 2024-11-04 | Before open | +4.90% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
IDYA financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $219M | -$114M | -$73M | -52.0% | $-1.28 |
| 2024 | $7M | -$274M | -$251M | -3921.1% | $-3.36 |
| 2023 | $23M | -$113M | -$118M | -483.0% | $-1.96 |
| 2022 | $51M | -$59M | -$91M | -115.2% | $-1.42 |
| 2021 | $28M | -$50M | -$58M | -178.1% | $-1.41 |
| 2020 | $20M | -$34M | $55M | -176.6% | $-1.40 |
| 2019 | $0 | -$42M | -$41M | – | – |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for IDYA
- 10-Q · Aug 4, 2026
- 8-K · Aug 4, 2026Results of operations, Financial statements and exhibits
- 8-K · Jun 23, 2026Shareholder vote, Other events
- 8-K · Jun 10, 2026Other events, Financial statements and exhibits
- 424B5 · Jun 9, 2026
- 424B5 · Jun 8, 2026
- 8-K · Jun 3, 2026Other events
- 8-K · Jun 1, 2026Regulation FD disclosure, Other events, Financial statements and exhibits
- 8-K · May 5, 2026Other events, Financial statements and exhibits
- 424B5 · May 5, 2026
Insider filing activity
IDYA insiders filed 1 Form 4 report in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
IDYA news
- Is IDEAYA Biosciences (IDYA) A Bargain Following Its ESMO 2026 Clinical Data?Oct 31, 2026 · finance.yahoo.com
- IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)Oct 30, 2026 · finance.yahoo.com
- Earnings Preview: Acadia Pharmaceuticals (ACAD) Q3 Earnings Expected to DeclineOct 28, 2026 · finance.yahoo.com
- IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Oct 27, 2026 · finance.yahoo.com
- IDE849 (SHR-4849) DLL3 TOP1 ADC Updated Phase 1 Results at ESMO 2026 Demonstrates Promising Anti-Tumor Activity and Preliminary Overall Survival Results in Relapsed Small Cell Lung Cancer and Neuroendocrine CarcinomasOct 23, 2026 · finance.yahoo.com
- William Blair Expands Biotech Research as Veteran Analyst Alethia Young Initiates CoverageOct 21, 2026 · finance.yahoo.com
- IDEAYA Biosciences and Servier Announce Data From Three Clinical Trials at ESMO 2026 Supporting the Potential of Darovasertib to Become a Foundational New Therapy for Patients Across the Treatment Journey of Uveal MelanomaOct 19, 2026 · finance.yahoo.com
About IDEAYA Biosciences, Inc.
IDEAYA Biosciences, Inc. (IDYA) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in DE. Its fiscal year ends in December.